A multicentre, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of Benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting β2-agonist in patients wtih uncontrolled asthma (SIROCCO)
Supported projects > Other Supported Projects by EU · 2014
Authors: Özlem GÖKSEL
2014-2016, Other Supported Projects by EU , R & D Project, Completed